Tumor antigens

Tsitologiya

Volumn 50, Issue 3, 2008, Pages 189-209

  Tyuryaeva, I I ^a  

^a INSTITUTE OF CYTOLOGY   (Russian Federation)

Author keywords

Cancer testis antigens; Differentiation antigens; Mutant tumor specific antigens; Onconeural antigens; Tumor antigens; Virus encoded antigens

Indexed keywords

CANCER VACCINE; NERVE PROTEIN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN; VIRUS T ANTIGEN;

ANIMAL; ARTICLE; CLASSIFICATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; ISOLATION AND PURIFICATION; MALE; MUTATION; NEOPLASM; ONCOGENE; TESTIS;

ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, VIRAL, TUMOR; CANCER VACCINES; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY; MALE; MUTATION; NEOPLASM PROTEINS; NEOPLASMS; NERVE TISSUE PROTEINS; ONCOGENES; TESTIS; TUMOR MARKERS, BIOLOGICAL;

EID: 43749120055     PISSN: 00413771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (195)

1. Russian source
2. Russian source
3. Russian source
4. Russian source
5. Russian source
6. Russian source
7. Russian source
8. Russian source
9. Russian source
10. Russian source
11. Russian source
12. Russian source
13. Russian source
14. Russian source
15. Russian source
16. Russian source
17. Russian source
18. Russian source
19. Russian source
20. Russian source
21. Russian source
22. Russian source
23. Russian source
24. Russian source
25. Russian source
26. Abelev G. I., Perova S. D., Khramkova N. I., Postnikova Z. A., Irlin I. S. 1963. Production of embryonal alphaglobulin by transplantsble mouse hepatomas. Transplantation. 1: 174-180.
27. Abelev G. I., Sell S. 1999. Tumor markers. Introduction. Semin. Cancer Biol. 9: 61-65.
28. Ambrosini G., Adida C., Altieri D. C. 1997. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3: 917-921.
29. Anichini A., Maccalli C., Mortarini R., Salvi S., Mazzocchi A., Squarcina P., Herlyn M., Parmiani G. 1993. Melanoma sells and normal melanocyte share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J. Exp. Med. 177: 989-998.
30. Baldwin R. W., Barker C. R. 1967. Antigenic composition of transplanted rat hepatomas originally induced 4-dimethylaminoazobenzene. Brit. J. Cancer. 21: 338-345.
31. Basombrio M. A. 1970. Search for common antigenicity among twenty-five sarcomas induced by methylcholanthrene. Cancer Res. 30: 2458-2462.
32. Basombrio M. A., Prehn R. T. 1972. Studies on the basis of diversity and time of appearance of chemically-induced tumors. Nat. Cancer Inst. Monogr. 35: 117-124.
33. Bast R. C., Jr., Klug T. L., St John E., Jenison E., Nilo J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L., Zurawski V. R., Jr., Knapp R. C. 1983. A radioimmunoassay using a monoclonal antibody to monitror the course of epithelial ovarian cancer. N. Engl. J. Med. 309: 883-887.
34. Baurain J. F., Colau D., van Baren N., Landry C., Martelange V., Vikkula M., Boon T., Coulie P. G. 2000. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J. Immunol. 164: 6057-6066.
35. Belli F., Testori A., Rivoltini L., Maio M., Andreola G., Sertoli M. R., Gallino G., Piris A., Cattelan A., Lazzari I., Carrabba M., Scita G., Santantonio C., Pilla L., Tragni G., Lombardo C., Arienli F., Marchiano A., Queirolo P., Bertolini F., Cova A., Lamaj E., Ascani L., Camerini R., Corsi M., Cascinelli N., Lewis J. J., Srivastava P., Parmiani G. 2002. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin Oncol 20: 4169-4180.
36. Bernal S. D., Speak J. A. 1984. Membrane in small cell carcinoma of the lung defined by monoclonal antibody SMI. Cancer Res. 44: 265-270.
37. Brändle D., Brasseur F., Weynants P., Boon T., Van den Eynde B. 1996. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma J Exp Med. 183: 2501-2508.
38. Bosch G. J., ten, Kessler J. H., Joosten A. M., Bres-Vloemans A. A., Geluk A., Godthelp B. C., van Bergen J., Melief C. J., Leeksma O. C. 1999. A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a) construct. Blood. 94: 1038-1045.
39. Buckanovich R., Posner J. B., Darnel R. B. 1993. Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron. 11: 657-672.
40. Busso D., Coden D. J., Hayashi M., Kasahara M., Cuasnicu P. S. 2005. Human testicular protein TPX1/CRISP-2: localization in spermatozoa, fate after capacitation and relevance for gamete interaction. Mol. Hum. Reprod. 11: 299-305.
41. Buzyn A., Osiankovitch M., Zerbib A., Kemula M., Connan F., Varet B., Guillet J. G., Choppin J. 1997. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes. Eur. J. Immunol. 27: 2066-2072.
42. Cambier N., Zhang Y., Vairo G., Kosmopoulos K., Metcalf D., Nocola N., Elefanty A. 1999. Expression of BCR-ABL in Ml myeloid leukemia cells induced differentiation without arresting proliferation. Oncogene. 18: 343-352.
43. Chang C. R., Martin R. G., Livingston D. M., Luborsky S. W., Hu C.-P., Mora P. T. 1979. Relationship between T-antigen and tumor-specific transplantation antigen in simian virus 40-transformed cells. J. Virol. 29: 69-75.
44. Charrad R.-S., Li Y., Delpech B., Balitrand B., Clay D., Jasmin C., Chominne Ch., Smadya-Ioffe F. 1999. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nature Med. 5: 669-676.
45. Chiari R., Foury F., De Plaen E., Baurain J. F., Thonnard J., Coulie P. G. 1999. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res. 59: 5785-5792.
46. Choudhury A., Kiessling R. 2004. Her-2/Neu as a paradigm of a tumor-specific target for therapy. Breast Disease. 20: 25-31.
47. Cilensek Z. M., Yehiely F., Kular R. K., Deiss L. P. 2002. A member of the GAFE family of tumor antigens is anti-apoptotic gene that confers resistance to Fas/CD95/APO-1, interferon-γ, taxol and γ-irradiation. Cancer Biol. Ther. 1: 380-387.
48. Coral S., Sigalotti L., Altomonte M., Engelsberg A., Colizzi F., Caltarossi I., Maraskovsky E., Jager E., Seliger B., Maio M. 2002. 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin. Cancer Res. 8: 2690-2695.
49. Coulie P. G., Lehmann F., Lethe B., Herman J., Lurquin C., Andrawiss M., Boon N. 1995. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Nat. Acad. Sci. USA. 92: 7976-7980.
50. Cunningham J., Graus F., Anderson N., Posner J. 1986. Partial characterization of the Purkinje cell antigens in paraneoplastic cerebellar degeneration. Neurology. 36: 1163-1168.
51. Daley G., van Etten R., Baltimore D. 1990. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 247: 824-830.
52. Dalmau J., Furneaux H. M., Cordon-Cardo C., Posner J. B. 1992. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Amer. J. Pathol. 141: 881-886.
53. Dalmau J., Furneaux H. M., Gralla R. J., Kris M. G., Posner J. B. 1990. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer - a quantitative western blot analysis. Ann. Neurol. 27: 544-552.
54. Dalmau J., Graus F., Cheung N. V., Rosenblum M. K., Ho A., Canete A., Depattre J. Y., Thompson S. J., Posner J. B. 1995. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitic in neuroblastoma and small cell lung cancer. Cancer. 75: 99-109.
55. Darnell R. B. 1996. Onconeural antigens and the paraneoplastic neurologic disordes: at the intersection of cancer, immunity and brain. Proc. Nat. Acad. Sci. USA. 93: 4529-4536.
56. Darnell R. B. 2004. Paraneoplastic neurologic disordes. Arch. Neurol. 61: 30-32.
57. Day E. D. 1965. Antigenic diversion in cancer. Proc. Amer. Assoc. Cancer Res. 6: 13-17.
58. Deb S. P. 2002. Function and dysfunction of the human oncoprotein MDM2. Front Biosci. 7: 235-243.
59. De Smet C., De Backer O., Faraoni I., Lurquin Ch., Brasseur F., Boonet T. 1996. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc. Nat. Acad. USA. 93: 7149-7153.
60. De Smet C., Lurquin C., Lethe B., Martelange V., Boon T. 1999. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Biol. 19: 7237-7335.
61. Dorshkind K. 1994. Transcriptional control points during lymphopoiesis. Cell. 79: 751-753.
62. Duan Z., Duan Y., Lamendola D. E., Yusuf R. Z., Naeem R., Penson R. T., Seiden M. V. 2003. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin. Cancer Res. 9: 2778-2785.
63. Echchakir H., Mami-Chouaib F., Vergnon I., Baurain J. F., Karanikas V., Chouaib S., Coulie P. G. 2001. A pont mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res. 61: 4078-4083.
64. Evans J. P. 2001. Fertillin b and other ADAMs as integrin ligands: insights into cell adhesion and fertilization. Bioessays. 23: 628-639.
65. Finger I. R., Harvey R. C., Moore R. C., Showe L. C., Croce C. M. 1986. A common mechanism of chromosomal translocation in T- and B-cell neoplasia. Science. 234: 982-985.
66. Flyer D. C., Pretell J., Campbell A. E., Liao W. S. L., Tevethia M. J., Taylor J. M., Tevethia S. S. 1983. Biology of simian virus (SV40) transplantation antigen (TrAg). X. Tumorogenic potential of mouse cells transformed by SV40 in high responder C58BL/6 mice and correlation with the persistence of SV40 TrAg, early proteins and viral sequences. Virology. 131: 207-220.
67. Fradet Y., Gordon-Cardo C., Thomson T., Daly M. E., Whitmore W. F., Lloyd K. O., Melamed M. R., Old L. J. 1984. Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc. Nat. Acad. Sci. USA. 81: 224-228.
68. Gambacorti-Passerini C., Grignani F., Arienti F., Pandolfi P. P., Pelicci P. G., Parmiani G. 1993. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood. 81: 1369-1375.
69. Gaudin C., Kremer F., Angevin E., Scott V., Triebel F. 1999. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J. Ummunol. 162: 1730-1738.
70. Gibson P., Gill J. H., Khan P. A., Seargent J. M., Martin S. W., Batman Ph. A., Griffith J., Bradley Ch., Double J. A., Bibby M. C., Loadman P. M. 2003. Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. Mol. Cancer Ther. 2: 527-534.
71. Gjertsen M. K., Bjorheim J., Saeterdal I., Myklebust J., Gaudernack G. 1997. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int. J. Cancer. 72: 784-790.
72. Gleiberman A., Abelev G. 1985. Cell position and cell interactions in expression of fetal phenotype of hepatocyte. Int. Rev. Cytol. 95: 229-266.
73. Glynn S. A., Gammell P., Heenan M., O'Connor R., Liang Y., Keenan J., Clynes M. 2004. A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin. Br. J. Cancer. 91: 1800-1807.
74. Goebel S. U., Iwamoto M., Raffeld M., Gibril F., Hou W., Serrano J., Jensen R. T. 2002. HER-2/neu expression and gene amplification in gastrinomas. Correlations with tumor biology, growth, and aggressiveness. Cancer Res. 62: 3702-3710.
75. Gold P., Freedman S. O. 1965. Specific carcinoembryonic antigens of the human digestive system. J. Exp. Med. 122: 467-481.
76. Gordon J. D., Vonderhcide R. H. 2002. Universal tumor antigens as target for immunotherapy. Cytotherapy. 4: 317-327.
77. Gorer P. A. 1956. Some recent work on tumor immunity. Adv. Cancer Res. 4: 149-186.
78. Graus F., Elkon K. B., Cordon-Cardo C., Posner J. B. 1986. Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Amer. J. Med. 80: 45-52.
79. Greaves M. F., Janossy G. 1978. Patterns of gene expression and the cellular origins of human leukaemias. Biochim. biophys. acta. 516: 193-230.
80. Grisham J. W. 1997. Interspecies comparison of liver carcinogenesis: implications for cancer risk assessment. Carcinogenesis. 18: 59-81.
81. Grizzi F., Chiriva-Internati M., Franceschini B., Hermonat P. L., Soda G., Lim S. H., Dioguardi N. 2003. Immunolocalization of sperm protein 17 in human testis and ejaculated spermatozoa. J. Histochem. Cytochem. 51: 1245-1248.
82. Grossman D., Kim P. J., Schechner J. S., Altieri D. C. 2001. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Nat. Acad. Sci. USA. 98: 635-640.
83. Gueguen M., Patard J.J., Gaugler B., Brasseur F., Renauld J. C., Van Cangh P. J., Boon T., Van den Eynde B. J. 1998. An antigen recognized by autologous CTLs on a human bladder carcinoma. J. Immunol. 160: 6188-6194.
84. Guidez F., Ivins S., Zhu J., Soderstrom M., Waxman S., Zelent A. 1998. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARα underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood. 91: 2634-2642.
85. Gure A. O., Wei I. J., Old L. J., Chen Y. T. 2002. The SSX gene family: characterization of 9 complete genes. Int. J. Cancer. 101: 448-453.
86. Habel K. 1962. Immunological determinants of polioma virus oncogenesis. J. Exp. Med. 115: 181-193.
87. Hahn W. C., Stewart S. A., Brooks M. W., York S. G., Eaton E., Kurachi A., Beijersbergen R. L., Knoll J. H., Meyerson M., Weinberg R. A. 1999. Inhibition of 1elomerase limits the growth of human cancer cells. Nat. Med. 5: 1164-1170.
88. Herbert B.-S., Pitts A. E., Baker S. I., Hamilton S. E., Wright W. E., Shay J. W., Corey D. R. 1999. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc. Nat. Acad. Sci. USA. 96: 14 276-14 281.
89. Himmelweit B. 1957. The collection papers of Paul Ehrlich. Oxford, England: Pergamon Press.
90. Hogan K. T., Eisinger D. P., Cupp S. B. III, Lekstrom K. J., Deacon D. D., Shabanowitz J., Hunt D. F., Endelhard V. H., Slingluff C. L., Jr., Ross M. M. 1998. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res. 58: 5144-5150.
91. Howe A., Aplin A., Alahari S., Juliana R. 1998. Integrin signaling and cell growth control. Curr. Opin. Cell Biol. 10: 220-231.
92. Huang S. K., Okamoto T., Morton D. L., Hoon D. S. 1998. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J. Investig. Dermatol. 111: 662-667.
93. Imam A., Drushella M., Taylor C. R., Tokes Z. A. 1985. Generation and immunohistochemical characterization of human monoclonal antibodies to mammary carcinoma cells. Cancer Res. 45: 263-271.
94. Ivanov S. V., Kuzmin I., Wei M.-H., Pack S., Geil L., Johnson B. E., Stanbridge E. J., Lerman M. I. 1998. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Nat. Acad. Sci. USA. 95: 12596-12601.
95. Ivanov V. A., Fel V. Ja. 1980. On some similarity between membrane antigens of the cell of Zajdela hepatoma and liver of rats subjected to a single 4-dimethyiaminoazobenzene injection. Neoplasma. 27: 745-750.
96. Ivanov V. A., Kushner V. P., Fel V. Ja. 1986. Antigenic diversion of rat liver cells characteristic of hepatocellular tumors after a single carcinogenic treatment and partial hepatectomy. Acta biol. hung. 36: 225-227.
97. Jungbluth A. A., Stockert E., Chen Y. T., Kolb D., Iversen K., Coplan K., Williamson B., Altorki N., Busam K. J., Old L. J. 2000. Monoclonal antibody MA454 reveals a heterogenous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumors. Br. J. Cancer. 83: 493-497.
98. Kamps M. A., Murre C., Sun X.-H., Baltimore D. 1990. A new homeobox gene contributes the DNA binding domain of the t(1; 19) translocation protein in pre-B ALL. Cell. 60: 547-555.
99. Karanikas V., Colau D., Baurain J. F., Chiari R., Thonnard J., Gutierrez-Roelens J., Goffinet C., Van Schaftingen E. V., Weynants P., Boon T., Coulie P. G. 2001. High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patients with long survival. Cancer Res. 61: 3718-3724.
100. Kawakami Y., Eliyahu S., Delgado C. H., Robbins P. F., Rivoltini L., Topauan S. L., Miki T., Rosenberg S. A. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Nat. Acad. Sci. USA. 91: 3515-3519.
101. Kawakami Y., Fujita N., Matsuzaki Y., Sakurai N., TsukamoIo M., Toda M., Sumimoto H. 2004. Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci. 95: 784-791.
102. Kawakami Y., Wang X., Shofuda T., Sumimoto H., Tupesis J., Fitzgerald E., Rosenberg S. 2001. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J. Immunol. 166: 2871-2877.
103. Keeney S., Giroux C. N., Kleckner N. 1997. Meiosis-specific DNA double-strand breaks are catalyzed by Spol 1, a member of a widely conserved protein family. Cell. 88: 375-384.
104. Khong H. T., Rosenberg S. A. 2002. Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J. Immunol. 168: 951-956.
105. Kim N. W., Piatyszek M. A., Prowse K. R., Harley C. B., West M. D., Ho P. L., Coviello G. M., Wright W. E., Weinrich S. L., Shay J. W. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science. 266: 2011-2015.
106. Kimmins S., Sassone-Corsi P. 2005. Chromatin remodeling and epigenetic features of germ cells. Nature. 434: 583-589.
107. Kinzler K. W., Vogelstein B. 1998. Landscaping the cancer terrain. Science. (Wash. DC). 280: 1036-1037.
108. Klipke M. L. 1974. Antigenicity of murine skin tumors induced by ultraviolet light. J. Natl. Cancer Inst. 53: 1333-1336.
109. Korsmeyer S. J. 1992. Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. Ann. Rev. Immunol. 10: 785-806.
110. Kossa N., Lucero G., Koziner B. 1996. Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor and interleukin 4 induce differentiation in the U-937 human monocytic leukemia cell line. Leuk. Limphoma. 1-2: 163-171.
111. Krutovskikh V. 2002. Implication of direct host-tumor intracellular interactions in non-immune host resistance to neoplastic growth. Semin. Cancer Biol. 12: 267-276.
112. Li F., Ackermann E. J., Bennett C. F., Rothennel A. L., Plescia J., Tognin S., Villa A., Marchisio P. C., Altieri D. C. 1999. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat. Cell Biol. 1: 461-466.
113. Li F., Ambrosini G., Chu E. Y., Plescia J., Tognin S., Marchisio P. C., Altieri D. C. 1998. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396: 580-584.
114. Li G., Miles A., Line A., Rees R. C. 2004. Identification of tumor antigens by serological analysis of cDNA expression cloning. Cancer Imminol. Immunother. 53: 139-143.
115. Li G., Zhang X. Y., Fan D. M., Hu J. L. 1994. Detection of antigen specific immune complexes in sera of gastric and esophageal cancer patients. Chin. Med. J. (Engl.). 107: 189-191.
116. Linard B., Bezieau S., Benlalam H., Labarriere N., Guilloux Y., Diez E., Jotereau F. 2002. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J. Ummunol. 168: 4802-4808.
117. Linnebacher M., Gebert J., Rudy W., Woerner S., Yan Y. P., Bork P., von Knebel Doeberitz M. 2001. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int. J. Cancer. 93: 6-11.
118. Livingston D. M., Bradley M. K. 1987. The simian virus 40 targe T antigen. A lot packed into little. Mol. Biol. Med. 4: 63-80.
119. Look A. Th. 1997. Oncogenic transcription factors in the human acute leukemias. Science. 278: 1059-1065.
120. Lupetti R., Pisarra P., Verrecchia A., Farina C., Nicolini G., Anichini A., Bordignon C., Sensi M., Parmiani G., Traversari C. 1998. Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocytes (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J. Exp. Med. 188: 1005-1016.
121. Luque F., Furneaux H., Ferziger R., Rosenblum M., Wray S., Schold S. C., Jr., Glantz M. J., Jaeckle K. A., Biran H., Lesser M. 1991. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann. Neurol. 29: 241-251.
122. Maecker B., Sherr D.-H., Shen C. et al. 1999. Targeting universal tumor antigens with cytotoxic T cells: potential of CYP1B1 for broadly applicable antigen-specific immunotherapy. Blood. 94S: 438.
123. Maeurer M. J., Gollin S. M., Martin D., Swaney W., Bryant J., Castelli C., Robbins P., Parmiani G., Storkus W. J., Lotze M. T. 1996. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Investig. 98: 1633-1641.
124. Mandelboim O., Berke G., Fridkin M., Feldman M., Eisenstein M., Eisenbach L. 1994. CTL induction by a tumor-associated antigen octapeptide derived from murine lung carcinoma. Nature. 369: 67-71.
125. Mandruzzato S., Brasseur F., Andry G., Boon T., van der Bruggen P. 1997. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 186: 785-793.
126. Masson P., Palsson B., Andren-Sandberg A. 1990. Cancer-associated tumor markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status. Br. J. Cancer. 62: 118-121.
127. McKeage K., Perry C. M. 2002. Trastuzumab. A review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 62: 209-243.
128. Monach P. A., Meredith S. C., Siegel C. T., Schreiber H. 1995. A unique tumor antigen produced by a single amino acid substitution. Immunity. 2: 45-59.
129. Mumberg D., Wick M., Schreiber H. 1996. Unique tumor antigens redefined as mutant tumor-specific antigens. Seminars in Immunology. 8: 289-293.
130. Murray G. I., Taylor M. C., McFadyen M. C., McKay J. A., Greenlee W. F., Burke M. D., Melvin W. T. 1997. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer. Res. 57: 3026-3031.
131. Nilsson O., Brezicka F. T., Holmgern J., Sorenson S., Svennerholm L., Yngvason F., Lindholm L. 1986. Detection of a ganglioside antigens associated with snall cell lung carcinomas using monoclonal antibodies directed against fucosyl-GM1. Cancer Res. 46: 1403-1407.
132. Novelino L., Castelli C., Parmani G. 2005. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol. Immunother. 54: 187-207.
133. Novellino L., Renkvist N., Rini F., Mazzocchi A., Rivoltini L., Greco A., Deho P., Squarcina P. F., Parmiani G., Castelli C. 2003. Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen. J. Immunol. 170: 6363-6370.
134. Ohminami H., Yasukawa M., Kaneko S., Yakushihin Y., Abe Y., Kasahara U. Y., Ishida Y., Fujita S. 1999. Fas-independent and nonapoptotic cytotoxicity mediated by a human CD4(+) T-cell clone directed against an acute myelogenous leukemia-associated DEK-CAN fusion peptide. Blood. 93: 925-935.
135. Park J., Kong G. H., Lee S. W. 2002. hMAGE-A1 overexpression reducer TNF-α cytotoxity in ME-180 cells. Mol. Cells. 14: 122-129.
136. Passoni L., Scardino A., Bertazzoli C., Gallo B., Coluccia A. M., Lemonnier F. A., Kosmatopoulos K., Gambacorti-Passerini C. 2002. ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. Blood. 99: 2100-2106.
137. Peterson K., Rosenblum M. K., Kotanides H., Posner J. B. 1992. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 42: 1931-1937.
138. Pieper R., Christian R. E., Gonzales M. I., Nishimura M. I., Gupta G., Settlage R. E., Shabanowitz J., Rosenberg S. A., Hunt D. F., Topalian S. L. 1999. Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J. Exp. Med. 189: 757-766.
139. Pousette A., Leijonhufvud P., Arver S., Kvist U., Pelttari J., Hoog C. 1997. Presence of synaptonemal complex protein 1 transversal filament-lile protein in human primary spermatocytes. Hum. Reprod. 12: 2414-2417.
140. Rabbitts T. H. 1998. LMO T-cell translocation oncogenes typify genes activated by chromosomal translocation that alter transcription and developmental processes. Genes and Development. 12: 2651-2657.
141. Ramakrishnan S., Eppenberger U., Mueller H., Shinkai Y., Narayanan R. 1998. Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res. 58: 622-625.
142. Ramquist T., Pallos D. O., DeAnda J., Ahrlund-Richter L., Reinholdsson G., Roberts T. M., Schaffhausen B. S., Dalianis T. 1988. Immunization against the polyoma tumor-specific transplantation antigen (TSTA) with polyoma T-antigen. Int. J. Cancer. 42: 123-128.
143. Ren P., Mehta P., Rush R. 1998. Inhibition of gap junctional intercellular communication by tumor promoters in connexin 43 and connexin 32-expressing liver cells: cell specificity and role of protein kinase C. Carcinogenesis. 19: 160-175.
144. Rimoldi D., Salvi S., Reed D., Coulie P., Jongeneel V. C., De Plaen E., Brasseur F., Rodriguez A. M., Boon T., Ceroitini J. C. 1999. cDNA and protein characterization of human MAGE-10. Int. J. Cancer. 82: 901-907.
145. Ripberger E., Linnebacher M., Schwitalle Y., Gebert J., von Knebel Doeberitz M. 2003. Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J. Clin. Immunol. 23: 415-423.
146. Robbins P. F., El-Gamil M., Li Y. F., Kawakami Y., Loftus D., Appella E., Rosenberg S. A. 1996. A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J. Exp. Med. 183: 1185-1190.
147. Roos P. H., Bolt H. M. 2005. Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1. Expert Opinion on Drug Metabolism and Toxicology. 1: 187-202.
148. Rosen S. T., Mulshine J., Guttitta F., Fedorco J., Carneu D., Gazdar A., Minna J. 1984. Analysis of human small lung cancer differentiation antigens using a panel of rat monoclonal antibodies. Cancer Res. 44: 2052-2061.
149. Rosenberg S. A., Tong-On P., Li Y., Riley J. P., El-Gamil M., Parkhurst M. R., Robbins P. F. 2002. Identifications of BING-4 cancer antigen translated from and alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy. J. Immunol. 168: 2402-2407.
150. Rudisky D., Hagios C., Bissel M. 2002. Tumors are unique organs defined by abnormal signaling and contact. Semin. Cancer Biol. 11: 87-95.
151. Saeterdal I., Bjorheim J., Lislerud K., Gjertsen M. K., Bukholm I. K., Olsen O. C., Nesland J. M., Eriksen J. A., Moller M., Lindblom A., Gaudernack G. 2001. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc. Nat. Acad. Sci. USA. 98: 13 255-13 260.
152. Sahin U., Türeci Ö., Chen Y. T., Seitz G., Villena-Heinsen C., Old L. J., Pfreundschuh M. 1998. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int. J. Cancer. 78: 387-389.
153. Sahin U., Türeci Ö., Schmitt H., Cochlovius B., Johannes T., Schmits R., Stenner F., Luo G., Schobert I., Pfreundschunb M. 1995. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Nat. Acad. Sci. USA. 92: 11 810-11 813.
154. Sasaki M., Kleinman H. K., Huber H., Deutzmann R., Yamada Y. 1988. The A chain has a unique globular domain and homology with the basement membrane proteoglycan and the laminin B chains. J. Biol. Chem. 263: 16 536-16 544.
155. Satoh S. 1972. A hetero-organic antigens of rat ascites hepatoma. Gann. 63: 579-590.
156. Scanlan M. J., Chen Y. T., Williamson B., Gure A. O., Stackert E., Gordon J. D., Türeci Ö., Sahin U., Pfreundschuh M., Old L. J. 1998. Characterization of human colon cancer antigens recognized by autologous antibodies. Int. H. Cancer. 76: 652-658.
157. Scanlan M. J., Sompson A. J., Old L. J. 2004. The cancer/testis genes: review, standartization, and commentary. Cancer Immunol. 4: 1-15.
158. Schmits R., Cochlovius B., Treitz G., Regitz E., Ketter R., Preuss K. D., Romeike B. F., Pfreundschuh M. 2002. Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas. Int. J. Cancer. 98: 73-77.
159. Seliger B., Maeurer M. J., Ferrone S. 2000. Antigen-processing machinery breakdown and tumor growth. Immunol. Today. 21: 455-464.
160. Sharkey M. S., Lizee G., Gonzalez M. I., Patel S., Topalian S. L. 2004. CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res. 64: 1595-1599.
161. Shay J. W., Bacchetti S. 1997. A survey of telomerase activity in human cancer. Eur. J. Cancer. 33: 787-791.
162. Showe L. C., Croce C. M. 1987. The role of chromosomal translocations in B- and T-cell neoplasia. Ann. Rev. Immunol. 5: 253-277.
163. Simpson A. J. G., Cballero O. L., Jungbluth A., Chen Y.-T., Old L. J. 2005. Cancer/testis antigens, gametogenesis and cancer. Nature Rev. Cancer. 5: 615-625.
164. Sjögren H. O. 1964. Transplantation methods as a tool for detection of tumor-specific antigens. Prog. Exp. Tumor Res. 6: 259-322.
165. Sjögren H. O., Hellstrtöm /., Klein G. 1961. Transplantation of polioma virus induced tumors in mice. Cancer Res. 21: 329-337.
166. Smith J. W., Longo D. L., Urba W. J., Clark J. W., Watson T., Beveridge J., Conlon K. C., Sznol M., Creekmore S. P., Alvord W. G. 1991. Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a. Blood. 78: 1664-1667.
167. Stunnenberg H. G., Garcia-Jimenez C., Betz J.L. 1999. Leukemia: the sophisticated subversion of hematopoiesis by nuclear receptor oncoproteins. Biochim. biophys. acta. 11423: F15-F33.
168. Tagliabue E., Menard S., Della Torre G., Barbanti P., Mariani-Constantini R., Porro G., Colnaghi M. 1985. Generation of monoclonal antibodies reacting with human epithelial ovarian cancer. Cancer Res. 45: 379-385.
169. Tajima K., Obata Y., Tamaki H., Yoshida M., Chen Y. T., Scanlan M.J., Old L. J., Kuwano H., Takahashi T., Takahashi T., Mitsudomi T. 2003. Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer. 42: 23-33.
170. Takeuchi H., Kuo C., Morton D. L., Wang H.-J., Hoon D. S. B. 2003. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res. 63: 441-448.
171. Tan K., Shaw A. L., Madsen B., Jensen K., Taylor-Papadimitriou J., Freemont P. S. 2003. Human PLU-1 Has transcription repression properties and interact with the developmental transcription factors BF-1 and PAX-9. J. Biol. Chem. 278: 20 507-20 513.
172. Tapparel C., Reymond A., Girardet C., Guillou L., Lyle R., Lamon C., Mutter P., Antonarakis S. E. 2003. The TPTE gene family: cellular expression, subcellular localization and alternative splicing. Gene. 323: 189-199.
173. Tenen D. G., Hromas R., Licht J. O., Zang D. E. 1997. Transcription factors, normal myeloid development, and leukemia. Blood. 90: 489-519.
174. Thirkill C. E., Fitzgerald R. C., Sergott A. M., Roth N. K., Tyler N. C., Kellner J. L. 1989. Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. N. Engl. J. Med. 321: 1589-1594.
175. Topalian S. L., Gonzalez M. I., Ward Y., Wang X., Wang R. F. 2002. Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme. Cancer Res. 62: 5505-5509.
176. Türeci Ö., Sahin U., Vollmar E., Siemer S., Gotten E., Seitz G., Parkkila A.-K., Shah G. N., Grubb J. H., Pfreundschuh M., Sly W. S. 1998a. Human carbonic anhydrase XII. cDNA cloning, expression, and chromosomal localization of a carbonic anhydrase gene that is overexpressed in some renal cell cancers. Proc. Nat. Acad. Sci. USA. 95: 7608-7613.
177. Türeci Ö., Sahin U., Zwick C., Koslowski M., Seitz G., Pfreundschuhet M. 1998b. Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc. Nat. Acad. Sci. USA. 95: 5211-5216.
178. Vedantham S., Camllel H., Colomb H. 1992. Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. Cancer Res. 52: 1056-1096.
179. Velculescu V. E., Madden S. L., Zhang L. et al. 1999. Analysis of human transcriptomes. Nat. Genet. 23: 387-388.
180. Vieta E., Berton M., Burger C., Kepron M., Lee W., Yin X. 1991. Memory B and T cells. Ann. Rev. Immunol. 9: 193-217.
181. Vigneron N., Ooms A., Morel S., Degiovanni G., Van Den Eynde B. J.
182. Vonderheide R. H., Hahn W. C., Schnitze J. L., Nadler L. M. 1999. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 10: 673-679.
183. Wang H. Y., Zhou J., Zhu K., Riker A. I., Marincola F. M., Wang R. F. 2002. Identification of a mutated fibronectin as a tumor antigen recognized by CD4+ T cells: its role in extracellular matrix formation and tumor metastasis. J. Exp. Med. 195: 1397-1406.
184. Wang R. F., Appella E., Kawakami Y., Kang X., Rosenberg S. A. 1996. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J. Exp. Med. 184: 2207-216.
185. Wang R. F., Wang X., Atwood A.C., Topalian S. L., Rosenberg S. A. 1999a. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science. 284: 1351-1354.
186. Wang R. F., Wang X., Rosenberg S. A. 1999b. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J. Exp. Med. 189: 1659-1668.
187. Weber J., Salgaller M., Samid D., Johnson B., Herlyn M., Lassam N., Treisman J., Rosenberg S. A. 1994. Expression of the MAGE-1 tumor antigen is upregulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res. 54: 1766-1771.
188. Weinberg R. A. 1989. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res. 49: 3713-3721.
189. Weinschenk T., Gouttefangeas C., Schirle M., Obermayr F., Walter S., Schoor O., Kurek R., Loeser W., Sichler K. H., Wernet D., Stevanovic S., Rammensee H. G. 2002. Integration functional genomica approach for the design of patient-individual antitumor vaccines. Cancer Res. 15: 5818-5827.
190. Wölfel T., Hauer M., Schneider J., Serrano M., Wölfel C., Klehmann-Hieb E., DePlaen E., Hankeln T., Meyer zum Büschenfelde K., Beach D. 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 269: 1281-1284.
191. Wright C. L., Beckett M. L., Starling J. J., Schellhammer P. F., Sieg S. M., Ladaga L. E., Poleskic S. 1983. Immunohistochemical localization of prostate carcinoma-associated antigens. Cancer Res. 43: 5509-5516.
192. Xu H. P., Yuan L., Shan J., Feng H. 2004. Localization and expression of TSP50 protein in human and rodent testes. Urology. 64: 826-832.
193. Yotnda P., Garcia G., Peuchmaur M., Grandchamp B., Duval M., Lemonnier F., Vilmer E., Langlade-Demoyen P. 1998. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J. Clin. Invest. 102: 455-458.
194. Yun C., Senju S., Fujita H., Tsuji Y., Irie A., Matsushita S., Nishimura Y. 1999. Augmentation of immune response by altered peptide ligands of the antigenic peptide in a human CD4+ T-cell clone reacting to TEL/AML1 fusion protein. Tissue Antigens. 54: 153-161.
195. Zorn E., Hercend T. 1999. A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur. J. Immunol. 29: 592-601.